Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Why won't NASA's Artemis 2 astronauts land on the moon when they get there? - 27 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!)
- 3UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- 4The most effective method to Arrange a Higher Medical caretaker Pay During Your Next New employee screening
- 5Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy
- The 2026 'Super Bowl of Astronomy' starts today — here's what's happening
- Sports Shoes of 2024: Upgrade Execution and Solace
- Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination
- The Best Portable Applications for Psychological wellness and Prosperity
- New UPS distribution center in Taiwan doubles capacity, productivity
- Invigorating Spots To Go Kayaking All over The Planet
- Activist vessel collides with krill trawler in Antarctic confrontation
- Abbott issues US device correction for some glucose monitors over faulty readings risk
- Flu cases spiking this holiday season, CDC data shows
